This Program team will discover new things about immunity to cancer and virus infection and translate the information into novel therapies in patients with blood or solid cancers. The approaches will include new cellular or antibody therapies, alone or in combination. We will determine new predictive biomarkers to better select patients for therapy. We will overcome treatment resistance, improve the safety of combination therapies, and determine their best scheduling and dosing.
Molecular Determinants Of Risk, Progression And Treatment Response In Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$15,161,573.00
Summary
The investigators, all associated with the Melanoma Institute Australia, have recruited numerous people and biospecimens in order to study the causes, subtypes and treatment strategies in melanoma. The team aims to develop a scientific basis for improved 1) management of individuals at high risk of melanoma development and progression, and 2) treatment of patients with early and disseminated melanoma, thereby contributing to improved prospects of successfully treating this dangerous cancer.
Human Epilepsy: Understanding Biology To Improve Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$16,657,948.00
Summary
Our team of neurologists, molecular geneticists, physiologists and brain imaging specialists and leads the world in the discovery of the genetic causes of epilepsy. Through this work we will identify genes underlying epilepsy and study how genetic variations result in the development of seizures. Advanced brain imaging will be used to understand the effects of genetic variation on brain structure and function. This study may lead to new diagnostic methods and treatments for epilepsy.
Biomedical research now routinely generates massive, complex datasets using next generation sequencing platforms and other high throughput “omics” technologies. Our unique program will develop powerful computational and statistical methods to analyse such data. We will apply these methods to a range of human diseases including cancer, and infectious and genetics disease, contributing to deeper insight into pathological states.
Linking Lifestyle And Molecular Biology To Inform Precision Public Health For Major Cancers
Funder
National Health and Medical Research Council
Funding Amount
$8,487,111.00
Summary
The Program of research seeks to increase our understanding of cancer risk. We will use our large collections of population and family-based datasets to conduct innovative analyses, improving our understanding of the roles that genetic, epigenetic and lifestyle factors play in our risk of breast, colorectal and prostate cancer. This information should allow us to better predict a person’s cancer risk, enabling public health interventions, such as screening, to be delivered more effectively and e ....The Program of research seeks to increase our understanding of cancer risk. We will use our large collections of population and family-based datasets to conduct innovative analyses, improving our understanding of the roles that genetic, epigenetic and lifestyle factors play in our risk of breast, colorectal and prostate cancer. This information should allow us to better predict a person’s cancer risk, enabling public health interventions, such as screening, to be delivered more effectively and economically to those most at risk.Read moreRead less
For 60 years, we have had only 3 effective cancer treatments: surgery, radiation and chemotherapy, often used in combination.The last 5 years have produced a powerful fourth treatment: the patient's own immune system.The long standing collaborations and synergies of our multi-disciplinary teams have already underpinned many recent advances in immune-based therapies: we are now poised to develop several further immunotherapies and on track to test them in patients during the term of this grant.
This proposal is for a team of researchers and clinicians to explore the molecular control of the lymphatic vasculature. This network of lymphatic vessels, located in organs throughout the body, is critical for regulation of tissue fluid and immune function. It will identify new molecular pathways controlling lymphatic vessels and their interactions with other cells in the body and identify new diagnostic approaches and molecular targets for medicines to treat human diseases including cancer.
Central to improving the management of patients with cancer is an understanding of the molecular drivers of cancer. Based on our fundamental discoveries about the role of cell growth and perturbed cell signalling as drivers of cancer we will use the integration of molecular and imaging biomarkers with targeted therapies to translate this knowledge into better outcomes for cancer patients with defined molecular drivers of their cancer.
Precision Nanomedicine-based Diagnostics And Therapeutics For Refractory Malignancies
Funder
National Health and Medical Research Council
Funding Amount
$7,329,484.00
Summary
The vast majority of cancer patients die of their disease due to the emergence of drug resistant cancer cells or metastatic disease that is diagnosed at late stages. Our program aims to develop new types of therapy to specifically target aggressive cancers. To detect cancer early and evaluate the effectiveness of cancer therapy, we will develop sensitive diagnostic tools and devices. This research has application to both childhood and adult cancers.